Brokerages Expect Tesaro (TSRO) to Post -$2.77 EPS

Brokerages expect Tesaro (NASDAQ:TSRO) to announce ($2.77) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Tesaro’s earnings, with estimates ranging from ($3.42) to ($2.19). Tesaro posted earnings of ($2.55) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 8.6%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, May 8th.

On average, analysts expect that Tesaro will report full-year earnings of ($9.53) per share for the current fiscal year, with EPS estimates ranging from ($11.51) to ($7.70). For the next year, analysts expect that the firm will post earnings of ($6.34) per share, with EPS estimates ranging from ($8.80) to ($2.54). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Tesaro.

Tesaro (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) EPS for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.96). The company had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $51.78 million. Tesaro had a negative return on equity of 126.44% and a negative net margin of 222.15%.



A number of research firms have recently weighed in on TSRO. Cowen dropped their price objective on Tesaro from $125.00 to $80.00 and set a “market perform” rating for the company in a research note on Tuesday, January 2nd. Piper Jaffray reaffirmed a “hold” rating and issued a $80.00 price objective on shares of Tesaro in a research note on Tuesday, January 2nd. Citigroup reaffirmed a “buy” rating and issued a $135.00 price objective (down previously from $216.00) on shares of Tesaro in a research note on Wednesday, December 20th. Zacks Investment Research lowered Tesaro from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $158.00 price objective on shares of Tesaro in a research note on Friday, January 12th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $129.26.

TSRO traded down $2.04 during midday trading on Friday, reaching $52.16. The company had a trading volume of 616,308 shares, compared to its average volume of 1,157,405. The stock has a market cap of $3,052.35, a price-to-earnings ratio of -5.72 and a beta of 1.34. The company has a quick ratio of 4.39, a current ratio of 4.74 and a debt-to-equity ratio of 1.75. Tesaro has a 1 year low of $50.67 and a 1 year high of $168.92.

In other news, SVP Orlando Oliveira sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $69.88, for a total value of $209,640.00. Following the completion of the sale, the senior vice president now directly owns 9,076 shares of the company’s stock, valued at approximately $634,230.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Grant C. Bogle sold 1,809 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $54.85, for a total value of $99,223.65. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 334,913 shares of company stock valued at $19,083,294 and have sold 13,042 shares valued at $760,526. 40.50% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. KBC Group NV lifted its stake in shares of Tesaro by 10.9% in the 3rd quarter. KBC Group NV now owns 5,606 shares of the biopharmaceutical company’s stock valued at $724,000 after purchasing an additional 553 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Tesaro by 2.9% in the 3rd quarter. Legal & General Group Plc now owns 38,297 shares of the biopharmaceutical company’s stock valued at $4,944,000 after purchasing an additional 1,079 shares during the last quarter. Exane Derivatives lifted its stake in shares of Tesaro by 137.1% in the 4th quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 1,123 shares during the last quarter. Aperio Group LLC lifted its stake in shares of Tesaro by 29.9% in the 4th quarter. Aperio Group LLC now owns 4,922 shares of the biopharmaceutical company’s stock valued at $408,000 after purchasing an additional 1,132 shares during the last quarter. Finally, Great West Life Assurance Co. Can lifted its stake in shares of Tesaro by 16.6% in the 3rd quarter. Great West Life Assurance Co. Can now owns 11,213 shares of the biopharmaceutical company’s stock valued at $1,385,000 after purchasing an additional 1,593 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Tesaro (TSRO) to Post -$2.77 EPS” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://dakotafinancialnews.com/2018/04/13/brokerages-expect-tesaro-tsro-to-post-2-77-eps.html.

Tesaro Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Get a free copy of the Zacks research report on Tesaro (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tesaro (NASDAQ:TSRO)

Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply